APA (7th ed.) Citation

Monk, B. J., Kauderer, J. T., Moxley, K. M., Bonebrake, A. J., Dewdney, S. B., Secord, A. A., . . . Aghajanian, C. (2018). A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecologic oncology, 151(3), 422-427. https://doi.org/10.1016/j.ygyno.2018.10.001

Chicago Style (17th ed.) Citation

Monk, Bradley J., James T. Kauderer, Katherine M. Moxley, Albert J. Bonebrake, Summer B. Dewdney, Angeles Alvarez Secord, Frederick R. Ueland, Carolyn M. Johnston, and Carol Aghajanian. "A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: An NRG Oncology/gynecologic Oncology Group Study." Gynecologic Oncology 151, no. 3 (2018): 422-427. https://doi.org/10.1016/j.ygyno.2018.10.001.

MLA (9th ed.) Citation

Monk, Bradley J., et al. "A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: An NRG Oncology/gynecologic Oncology Group Study." Gynecologic Oncology, vol. 151, no. 3, 2018, pp. 422-427, https://doi.org/10.1016/j.ygyno.2018.10.001.